NCT05577819 Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
| NCT ID | NCT05577819 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Transthyretin Amyloidosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 515 participants |
| Start Date | 2020-10-02 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 515 participants in total. It began in 2020-10-02 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
Eligibility Criteria
Inclusion Criteria: * Patients with a confirmed diagnosis of HFpEF. * Age ≥65 years old Exclusion Criteria: * End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min) * no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc * Negative 99mTc-pyrophosphate scan within a year * Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan * Known diagnosis of amyloidosis * Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)
Contact & Investigator
Hanna K Gaggin, MD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT05577819 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Transthyretin Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05577819 currently recruiting?
Yes, NCT05577819 is actively recruiting participants. Contact the research team at ajmacher@mgh.harvard.edu for enrollment information.
Where is the NCT05577819 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05577819 clinical trial?
NCT05577819 is sponsored by Massachusetts General Hospital. The principal investigator is Hanna K Gaggin, MD at Massachusetts General Hospital. The trial plans to enroll 515 participants.